1Sowers JR, Neutel JM, Saunders E, et al. Antihypertensive effi- cacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes[J] J Clin Hypertens (Greenwich), 2006,8(7) :470-480.
3Cushman WC, Neutel JM, Saunders E, et al. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy [J] Am J Geriatr Cardiol,2008,17(1) :27-36.
二级参考文献7
1Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension, 2003,42:239-246.
2Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet,2000,29;356:366-372.
3Howe P, Phillips P, Saini R, et al.The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. Clin Exp Hypertens. 1999,21:1373-1396.
5European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens,2003,21:1011-1053.
6Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.Lancet. 1998,351:1755-1762.
2Lam CS, Carson PE, Anand IS, et al. Sex differences in clinical char- acteristics and outcomes in elderly patients with heart failure and pre- served ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial [J] . Circ Heart Fail, 2012, 5 (5) : 571-578.
